+ All Categories
Home > Documents > Biosimilar Education

Biosimilar Education

Date post: 22-Apr-2015
Category:

Documents
Upload: industry-standard-research
View: 537 times
Download: 0 times
Download Report this document
Share this document with a friend
Description:
In this infographic, ISR explores what US patients know about Biologic and Biosimilar Medicines, who they’re consulting to make decisions, and how a small amount of information can affect that.
1
Transcript
Page 1: Biosimilar Education
Recommended
Rituximab Biosimilar Brochure

Rituximab Biosimilar Brochure

Health & Medicine

Free to sell your biosimilar?

Free to sell your biosimilar?

Documents

Eurofins Biosimilar Trastuzumab Bioanalytics

Eurofins Biosimilar Trastuzumab Bioanalytics

Science

TGA pharmacovigilance for biosimilar medicines · TGA pharmacovigilance for biosimilar medicines Biosimilar Awareness Initiative Reference Group Meeting- 29 November 2016. Dr Bronwen

TGA pharmacovigilance for biosimilar medicines · TGA pharmacovigilance for biosimilar medicines Biosimilar Awareness Initiative Reference Group Meeting- 29 November 2016. Dr Bronwen

Documents

EXTENDED REPORT A randomised, single-blind, single-dose ... · (Celltrion), ABP 501 adalimumab biosimilar, ABP 798 rituximab biosimilar and ABP 710 infliximab biosimilar (Amgen).

EXTENDED REPORT A randomised, single-blind, single-dose ... · (Celltrion), ABP 501 adalimumab biosimilar, ABP 798 rituximab biosimilar and ABP 710 infliximab biosimilar (Amgen).

Documents

China Biosimilar

China Biosimilar

Documents

The Impact of Biosimilar Competition

The Impact of Biosimilar Competition

Documents

Biosimilar Biological Products

Biosimilar Biological Products

Documents

Filgrastim Biosimilar Brochure

Filgrastim Biosimilar Brochure

Business

CISummit 2013: Steve Gullans & Gregory Gallo, The BioSimilar Age: How to Promote a Biosimilar and Defend a Franchise from a BioSimilar Attack

CISummit 2013: Steve Gullans & Gregory Gallo, The BioSimilar Age: How to Promote a Biosimilar and Defend a Franchise from a BioSimilar Attack

Business

Clinical Immunogenicity and the Biosimilar paradigm - …€¦ · Clinical Immunogenicity and the Biosimilar paradigm ... biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB

Clinical Immunogenicity and the Biosimilar paradigm - …€¦ · Clinical Immunogenicity and the Biosimilar paradigm ... biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB

Documents

TGA pharmacovigilance for biosimilar medicines · 2019-12-29 · TGA pharmacovigilance for biosimilar medicines Biosimilar Awareness Initiative Reference Group Meeting- 29 November

TGA pharmacovigilance for biosimilar medicines · 2019-12-29 · TGA pharmacovigilance for biosimilar medicines Biosimilar Awareness Initiative Reference Group Meeting- 29 November

Documents

DESIGN OF BIOSIMILAR BIOANALYTICAL PROGRAMS: … · JANKA RYDING, EBF 2019 DESIGN OF BIOSIMILAR BIOANALYTICAL PROGRAMS: STRATEGIES, PERSPECTIVES •Currently >20 biosimilar medicines

DESIGN OF BIOSIMILAR BIOANALYTICAL PROGRAMS: … · JANKA RYDING, EBF 2019 DESIGN OF BIOSIMILAR BIOANALYTICAL PROGRAMS: STRATEGIES, PERSPECTIVES •Currently >20 biosimilar medicines

Documents

April 2020 - XBrane · 3 XBRANE BIOPHARMA –THE ONLY NORDIC BIOSIMILAR DEVELOPER Low-risk high potential lead phase III biosimilar •Xlucane (Lucentis®biosimilar) is a low-riskproduct

April 2020 - XBrane · 3 XBRANE BIOPHARMA –THE ONLY NORDIC BIOSIMILAR DEVELOPER Low-risk high potential lead phase III biosimilar •Xlucane (Lucentis®biosimilar) is a low-riskproduct

Documents

Guidelines for Registration of Biosimilar

Guidelines for Registration of Biosimilar

Documents

Quality-focused Development Strategy of Biosimilar Product · • Monitor throughout the entire biosimilar development period Biosimilar mAb has to take in consideration of the largest

Quality-focused Development Strategy of Biosimilar Product · • Monitor throughout the entire biosimilar development period Biosimilar mAb has to take in consideration of the largest

Documents

Leveraging Patient Support Programs in Biologic-Biosimilar ...€¦ · Leveraging Patient Support Programs in Biologic-Biosimilar Competitive Landscape . Biologics are facing biosimilar

Leveraging Patient Support Programs in Biologic-Biosimilar ...€¦ · Leveraging Patient Support Programs in Biologic-Biosimilar Competitive Landscape . Biologics are facing biosimilar

Documents

EGA Handbook on Biosimilar Medicines

EGA Handbook on Biosimilar Medicines

Documents